{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:38:10Z","timestamp":1793813890160,"version":"4.6.1"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.canlet.2026.218350","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:11:29Z","timestamp":1771690289000},"page":"218350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics"],"prefix":"10.1016","volume":"645","author":[{"given":"Shiv","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9492-3249","authenticated-orcid":false,"given":"Sanjay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218350_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13073-024-01388-3","article-title":"Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients","volume":"16","author":"Zhang","year":"2024","journal-title":"Genome Med."},{"key":"10.1016\/j.canlet.2026.218350_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2026.218350_bib3","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/14728222.2022.2170779","article-title":"The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting","volume":"26","author":"Furukawa","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2026.218350_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218350_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218350_bib6","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218350_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103354","article-title":"Delivery technologies for T cell gene editing: applications in cancer immunotherapy","volume":"67","author":"Atsavapranee","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2026.218350_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018786","article-title":"CAR-T cell therapy in triple-negative breast cancer: hunting the invisible devil","volume":"13","author":"Nasiri","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218350_bib9","article-title":"Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines","volume":"11","author":"Swetha","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.canlet.2026.218350_bib10","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218350_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000455820","article-title":"Biological subtypes of triple-negative breast cancer","volume":"12","author":"Hubalek","year":"2017","journal-title":"Breast Care"},{"key":"10.1016\/j.canlet.2026.218350_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12672-025-02542-y","article-title":"Advances in mRNA vaccine therapy for breast cancer research","volume":"16","author":"Li","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.canlet.2026.218350_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/bs.ircmb.2024.05.001","article-title":"DNA damage response and neoantigens: a favorable target for triple-negative breast cancer immunotherapy and vaccine development","volume":"389","author":"Subbarayan","year":"2024","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218350_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16112094","article-title":"Triple negative breast cancer: molecular subtype-specific immune landscapes with therapeutic implications","volume":"16","author":"Syrnioti","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218350_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1601773","article-title":"Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling","volume":"16","author":"Kraja","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218350_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17020228","article-title":"Triple-negative breast cancer progression and drug resistance in the context of epithelial\u2013mesenchymal transition","author":"B\u0142aszczak","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218350_bib17","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/s41467-025-57123-y","article-title":"Synthetic short mRNA prevents metastasis via innate-adaptive immunity","volume":"16","author":"Hayashi","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218350_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081864","article-title":"Regulation of ZEB1 function and molecular associations in tumor progression and metastasis","volume":"14","author":"Perez-Oquendo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218350_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1344272","article-title":"Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors","volume":"15","author":"Ouyang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218350_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218350_bib21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218350_bib22","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218350_bib23","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/j.clbc.2018.07.023","article-title":"Genetic markers in triple-negative breast cancer","volume":"18","author":"Sporikova","year":"2018","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218350_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.breast.2018.08.106","article-title":"Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: an indication to immunotherapy?","volume":"42","author":"Tessari","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.canlet.2026.218350_bib25","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","article-title":"Treatment of patients with metastatic cancer using a major histocompatibility complex class II-Restricted T-Cell receptor targeting the cancer germline antigen MAGE-A3","volume":"35","author":"Lu","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218350_bib26","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218350_bib27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","article-title":"Tumor microenvironment and immunotherapy for triple-negative breast cancer","volume":"12","author":"Guo","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.canlet.2026.218350_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","article-title":"Tumor microenvironment: barrier or opportunity towards effective cancer therapy","volume":"29","author":"Tiwari","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.canlet.2026.218350_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2319856121","article-title":"IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation","volume":"121","author":"Tilsed","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218350_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218350_bib31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ymthe.2019.01.018","article-title":"The emerging role of in vitro-transcribed mRNA in adoptive T cell immunotherapy","volume":"27","author":"Foster","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218350_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16010124","article-title":"Engineered adoptive T-Cell therapies for breast cancer: current progress, challenges, and potential","volume":"16","author":"Chamorro","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218350_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12935-024-03615-8","article-title":"Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer","volume":"25","author":"Marei","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2026.218350_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/annonc\/mdq325","article-title":"Cancer-testis antigen expression in triple-negative breast cancer","volume":"22","author":"Curigliano","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218350_bib35","doi-asserted-by":"crossref","first-page":"13493","DOI":"10.1073\/pnas.0906840106","article-title":"CT-X antigen expression in human breast cancer","volume":"106","author":"Grigoriadis","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218350_bib36","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.clbc.2013.05.001","article-title":"Mesothelin expression and survival outcomes in triple receptor negative breast cancer","volume":"13","author":"Parinyanitikul","year":"2013","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218350_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153875","article-title":"Cancer-testis antigens in triple-negative breast cancer: Role and potential utility in clinical practice","volume":"13","author":"Lam","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218350_bib38","article-title":"Adoptive cell therapy for solid tumors: current status in melanoma and next-generation therapies","volume":"44","author":"Haanen","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Edu. Book"},{"key":"10.1016\/j.canlet.2026.218350_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-024-01436-7","article-title":"Personalized neoantigen cancer vaccines: current progression, challenges and a bright future","volume":"24","author":"Wu","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218350_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13092213","article-title":"Neoantigen-driven immunotherapy in triple-negative breast cancer: emerging strategies and clinical potential","volume":"13","author":"Shatalov","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2026.218350_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102721","article-title":"mRNA therapeutics: transforming medicine through innovation in design, delivery, and disease treatment","volume":"36","author":"Ige","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2026.218350_bib42","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218350_bib43","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218350_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15507","article-title":"Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy","volume":"8","author":"Su","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218350_bib45","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2147\/IJN.S360500","article-title":"pH-Responsive hyaluronic acid nanoparticles for enhanced triple negative breast cancer therapy","volume":"17","author":"Zeng","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2026.218350_bib46","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/acsptsci.4c00597","article-title":"Nanoparticle-mediated mRNA delivery to Triple-Negative Breast Cancer (TNBC) patient-dPatient-Derived Xenograft (PDX) tumors","volume":"8","author":"El-Sahli","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.canlet.2026.218350_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.coi.2012.01.007","article-title":"The role of mRNA translation in direct MHC class I antigen presentation","volume":"24","author":"Apcher","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2026.218350_bib48","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/925135","article-title":"CD4+T cells: differentiation and functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.canlet.2026.218350_bib49","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nmat3776","article-title":"Stimuli-responsive nanocarriers for drug delivery","volume":"12","author":"Mura","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.canlet.2026.218350_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41392-021-00631-2","article-title":"Recent progress in targeted delivery vectors based on biomimetic nanoparticles","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218350_bib51","unstructured":"M. Akhtar, N. Nida, G. Azka, P. Rabea, K. Sana, K. Saba, A. Javed, H. Jamia, J. Hamdard,and Explicating the transformative role of artificial intelligence in designing targeted nanomedicine, Expet Opin. Drug Deliv., null-null.."},{"key":"10.1016\/j.canlet.2026.218350_bib52","author":"Randomized","year":"2022"},{"key":"10.1016\/j.canlet.2026.218350_bib53","series-title":"A Phase 1 Study to Evaluate the Efficacy and Safety of HRXG-K-1939 and Adebrelimab in Patients with Advanced Solid Tumors","year":"2023"},{"key":"10.1016\/j.canlet.2026.218350_bib54","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-3035","article-title":"Abstract 3035: phase I trial of alpha-lactalbumin vaccine in high-risk operable triple-negative breast cancer","volume":"83","author":"Budd","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218350_bib55","series-title":"I. National Cancer","year":"2022"},{"key":"10.1016\/j.canlet.2026.218350_bib56","series-title":"A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients with Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy","year":"2015"},{"key":"10.1016\/j.canlet.2026.218350_bib57","series-title":"A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, PD1\/PD-L1 Inhibitor-Refractory Melanoma, and Pretreated Non-small Cell Lung Cancer","year":"2021"},{"key":"10.1016\/j.canlet.2026.218350_bib58","series-title":"I. National Cancer","article-title":"Evaluation of the safety and immunogenicity of vaccination with multiple synthetic peptides in participants with advanced breast cancer","year":"2006"},{"key":"10.1016\/j.canlet.2026.218350_bib59","article-title":"Randomized phase 2 clinical trial of nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab in patients with metastatic triple negative","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218350_bib60","series-title":"A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple-Negative Breast Cancer","year":"2019"},{"key":"10.1016\/j.canlet.2026.218350_bib61","series-title":"A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with Pembrolizumab in HLA-A2+ Patients with Metastatic Triple Negative Breast Cancer (TNBC)","year":"2017"},{"key":"10.1016\/j.canlet.2026.218350_bib62","series-title":"A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone Vs. Neoantigen DNA Vaccine plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy","year":"2017"},{"key":"10.1016\/j.canlet.2026.218350_bib63","series-title":"A Phase Iia Study of Dendritic Cell Vaccines Against Her2\/Her3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC) or Hormone Receptor Positive (HR+) Breast Cancer","year":"2020"},{"key":"10.1016\/j.canlet.2026.218350_bib64","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218350_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9503","article-title":"Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201\/KEYNOTE-942 trial","volume":"41","author":"Khattak","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218350_bib66","series-title":"A Phase 1a\/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Tumors","year":"2017"},{"key":"10.1016\/j.canlet.2026.218350_bib67","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-CT301","article-title":"Abstract CT301: a phase Ib study to evaluate RO7198457, an individualized neoantigen specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors","volume":"80","author":"Lopez","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218350_bib68","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.2147\/CMAR.S185176","article-title":"The clinical promise of immunotherapy in triple-negative breast cancer","volume":"10","author":"Vikas","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.canlet.2026.218350_bib69","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2021.10.027","article-title":"Therapeutic vaccines for breast cancer: has the time finally come?","volume":"160","author":"Corti","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218350_bib70","series-title":"A Phase 1\/2 Study of Galinpepimut-S in Combination with Pembrolizumab (MK 3475) in Patients with Selected Advanced Cancers","year":"2018"},{"key":"10.1016\/j.canlet.2026.218350_bib71","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s12276-023-01118-6","article-title":"Understanding nucleic acid sensing and its therapeutic applications","volume":"55","author":"Kong","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218350_bib72","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218350_bib73","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","volume":"22","author":"Peng","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2026.218350_bib74","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1210\/er.2018-00163","article-title":"Thyroid dysfunction and diabetes mellitus: two closely associated disorders","volume":"40","author":"Biondi","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.canlet.2026.218350_bib75","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13167-017-0101-y","article-title":"Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?","volume":"8","author":"Vadal\u00e0","year":"2017","journal-title":"EPMA J."},{"key":"10.1016\/j.canlet.2026.218350_bib76","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218350_bib77","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.canlet.2026.218350_bib78","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41467-017-00505-8","article-title":"Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers","volume":"8","author":"Moffett","year":"2017","journal-title":"Nat. Commun."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T21:34:09Z","timestamp":1774388049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526001138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":78,"alternative-id":["S0304383526001138"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218350","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218350"}}